key: cord-0315650-suqkidrm authors: Tseng, H. F.; Ackerson, B. K.; Luo, Y.; Sy, L. S.; Talarico, C.; Tian, Y.; Bruxvoort, K.; Tupert, J. E.; Florea, A.; Ku, J. H.; Lee, G. S.; Choi, S. K.; Takhar, H. S.; Aragones, M.; Qian, L. title: Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants date: 2022-01-08 journal: nan DOI: 10.1101/2022.01.07.22268919 sha: 8f2c55e03fae784bf556fcf067542c9dc8ec2222 doc_id: 315650 cord_uid: suqkidrm Background The recently emerged SARS-CoV-2 omicron variant raised concerns around potential escape from vaccine-elicited immunity. Limited data are available on real-world vaccine effectiveness (VE) of mRNA-1273 against omicron. Here, we report VE of 2 or 3 mRNA-1273 doses against infection and hospitalization with omicron and delta, including among immunocompromised individuals. Methods This test negative study was conducted at Kaiser Permanente Southern California. Cases were individuals aged [≥]18 years testing positive by RT-PCR with specimens collected between 12/6/2021 and 12/23/2021 with variant determined by spike gene status. Randomly sampled test negative controls were 5:1 matched to cases by age, sex, race/ethnicity, and specimen collection date. Conditional logistic regression models were used to evaluate adjusted odds ratio (aOR) of vaccination with mRNA-1273 doses between cases and controls. VE(%) was calculated as (1-aOR)x100. Results 6657 test positive cases (44% delta, 56% omicron) were included. The 2-dose VE against omicron infection was 30.4% (95% CI, 5.0%-49.0%) at 14-90 days after vaccination and declined quickly thereafter. The 3-dose VE was 95.2% (93.4%-96.4%) against delta infection and 62.5% (56.2%-67.9%) against omicron infection. The 3-dose VE against omicron infection was low among immunocompromised individuals (11.5%; 0.0%-66.5%). None of the cases (delta or omicron) vaccinated with 3 doses were hospitalized compared to 53 delta and 2 omicron unvaccinated cases. Conclusions VE of 3 mRNA-1273 doses against infection with delta was high and durable, but VE against omicron infection was lower. VE against omicron infection was particularly low among immunocompromised individuals. No 3-dose recipients were hospitalized for COVID-19. The recently emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron (B.1.1.529) variant contains multiple novel spike (S) protein mutations, raising concerns about escape from naturally acquired or vaccine-elicited immunity. 1 Several in vitro studies reported reduced vaccine-induced neutralization activity against omicron. 2, 3 Specifically, sera from individuals vaccinated with 2 doses of mRNA coronavirus disease 2019 (COVID-19) vaccines, including mRNA-1273 (Moderna COVID-19 vaccine), showed substantial reductions in neutralization activity against omicron compared with wild-type SARS-CoV-2. 2, 4, 5 However, an mRNA-1273 booster increased neutralization activity against omicron, albeit lower than wild-type. 2 As omicron has a deletion at positions 69-70, omicron-positive specimens exhibit Sgene target failure (SGTF). To provide timely results, we used SGTF as a marker for omicron in specimens collected during December 2021 for these analyses. The US Food and Drug Administration (FDA) and World Health Organization advised that SGTF from select COVID-19 RT-PCR assays, including the Thermo Fisher TaqPath TM COVID-19 Combo kits, can be used as a screening method for omicron; 7,8 SGTF has served as a proxy in the United Kingdom for identifying omicron. 9,10 In Southern California where delta was the dominant strain before omicron, 11 and the proportion of SGTF among SARS-CoV-2 positive specimens increased from 2.7% to 83.9% from 12/06/2021 to 12/23/2021, SGTF can be used as a proxy for omicron, while positive specimens negative for SGTF can be considered delta. Herein, we report VE of mRNA-1273 against infection and hospitalization with omicron and delta within the Kaiser Permanente Southern California (KPSC) healthcare system in the United States. KPSC is an integrated healthcare system that provides care to over 4.6 million sociodemographically diverse health plan members at 15 hospitals and associated medical offices across Southern California. Comprehensive electronic health records (EHRs) included information on demographics, immunizations, diagnoses, laboratory tests, procedures, and pharmacy records. KPSC began administering mRNA-1273 on 12/18/2020. Outside COVID-19 vaccinations were imported into members' EHR daily from external sources, including the California Immunization Registry, Care Everywhere (system on the Epic EHR platform that allows healthcare systems to exchange patients' medical information), claims (e.g., retail pharmacies), and self-report by members (with valid documentation). Molecular diagnostic testing for SARS-CoV-2 is available to members who request it for any reason, before procedures and hospital admissions, with and without symptoms. Specimens were primarily collected using nasopharyngeal/oropharyngeal swabs (for symptomatic individuals) or saliva (for asymptomatic individuals). Specimens were delta cases (Table 1) . 13.0% and 14.9% of omicron cases in the 2-dose and 3-dose analyses, respectively, had a history of COVID-19 versus 1.7% and 2.2% of delta cases. Table 2 shows VE against delta and omicron infection or hospitalization. Overall, the 1dose VE was 60.2% (95% CI, 42.6%-72.3%) and 20.3% (0.0%-39.8%), the 2-dose VE was 60.7% (56.5%-64.5%) and 0.0% (0.0%-3.1%), and the 3-dose VE was 95.2% (93.4%-96.4%) and 62.5% (56.2%-67.9%) against delta and omicron infection, respectively. In analyses of 2-dose VE against delta infection by time since receipt of dose 2, VE at 14-90 days was 82.8% (69.6%-90.3%) and subsequently declined, with VE of 63.6% (51.8%-72.5%) at 91-180 days, 61.4% (56.8%-65.5%) at 181-270 days, and 52.9% (43.7%-60.5%) at >270 days (Table 2, Figure 1 ). The 2-dose VE against omicron infection was 30.4% (5.0%-49.0%) at 14-90 days and declined quickly to 15.2% (0.0%-30.7%) at 91-180 days and 0.0% after 180 days. The 3-dose VE against delta infection was >90%, regardless of whether the third dose was received before or after 10/20/2021. For vaccinated cases, the median number of days from vaccination to positive test date was 35 and 112 days if dose 3 was received after 10/20/2021 or on and before that day, respectively. However, the VE against omicron infection was 63.6% (57.4%-68.9%) if dose 3 was received after 10/20/2021 (for vaccinated cases, median number of days from vaccination to positive test date was 36 days) and 39.1% (3.8%-61.5%) if received on or before 10/20/2021 (for vaccinated cases, median number of days from vaccination to positive test date was 103 days; Table 2 ). These estimates were similar in analyses excluding immunocompromised individuals, except All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 8, 2022. ; https://doi.org/10.1101/2022.01.07.22268919 doi: medRxiv preprint that the VE against omicron infection increased to 49.0% (12.6%-70.2%) among immunocompetent individuals who received dose 3 before or on 10/20/21 (Table 2, Figure 2 ). Only 4 vaccinated delta cases were hospitalized, of whom one received 1 dose and 3 received 2 doses (Table 2 ). Only 2 vaccinated omicron cases were hospitalized; both received 2 doses. None of the delta or omicron cases vaccinated with 3 doses were hospitalized. In comparison, 53 delta and 2 omicron unvaccinated cases were hospitalized ( Table 2) . Table 3 presents the 3-dose VE against infection by subgroups. The 3-dose VE against delta was >95% across age, sex, and race/ethnicity groups but lower in the immunocompromised population (72.2% [12.2%-91.2%]). The 3-dose VE against omicron was 63.1% (56.6%-68.6%) in those <65 years and 57.1% (14.2%-78.6%) in those ≥ 65 years and only 11.5% (0.0%-66.5%) in the immunocompromised population compared to 63.6% (57.4%-68.9%) in the immunocompetent population. We evaluated the effectiveness of mRNA-1273 against the highly mutated omicron variant in a sociodemographically diverse population in a real-world setting. Between 12/6/2021 and 12/23/2021, the rapidly increasing proportion of omicron positive specimens indicated unprecedented transmissibility and raised concerns over protection conferred by currently authorized or licensed COVID-19 vaccines. Our study demonstrates that while VE of 2 doses of mRNA-1273 against infection with delta is high and wanes slowly, consistent with our previous findings, 6,12 the 2-dose VE against All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 8, 2022. ; after a primary course of BNT162b2 vaccine, VE against omicron infection was initially 70% after a BNT162b2 booster, dropping to 45% after ≥ 10 weeks, but stayed around 70%-75% for up to 9 weeks after an mRNA-1273 booster. 10 A growing number of reports indicate that omicron disease is less severe than delta disease, resulting in a lower risk of hospitalization. 1, 20 This may reflect greater replication of omicron in the upper versus lower respiratory tract, which may also contribute to more efficient transmission, resulting in increased absolute 21 numbers of hospitalizations. Booster vaccination has the potential to decrease hospital burden and improve outcomes. 22 While the number of cases and follow-up period were not sufficient in our study or other studies to assess potential waning VE against hospitalization with omicron, our results of waning VE against infection with omicron after dose 3 of mRNA-1273 underscores the importance of monitoring VE against hospitalization with omicron. This study provides novel data complementing recent reports of the effectiveness of other COVID-19 vaccines against omicron and has several strengths and limitations. Testing for SARS-CoV-2 infection was readily available among KPSC members, including drive-through testing and self-scheduled test appointments. Furthermore, we used a highly specific and sensitive RT-PCR test and monitored variant proportions at KPSC, allowing us to quickly assess VE of mRNA-1273 against omicron. Second, we considered all SGTF specimens as omicron, rather than specifying a Ct value threshold, although this may have overestimated omicron detection. Our rate of SGTF closely mirrored regional trends in omicron emergence from the CDC. 11 Furthermore, based on whole genome sequencing results received for a subset of 227 positive specimens, we confirmed that all 6 omicron cases exhibited SGTF, and the remaining 221 delta cases All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 8, 2022. ; https://doi.org/10.1101/2022.01.07.22268919 doi: medRxiv preprint were all negative for SGTF. Third, this study was representative of a large, diverse racial, ethnic, and socioeconomic population in Southern California, but may be less representative of other populations. However, analysis of the effectiveness of mRNA-1273 against delta and omicron in parallel provided an internal comparator that put results in context. 12 Fourth, some immunocompetent members who received a third dose before the 10/21/2021 ACIP recommendation may have received a 100-µg dose rather than a 50-µg booster dose of mRNA-1273. However, we were not able to clearly assess the difference, as dosage information was not available from external vaccination records. Finally, the number of hospitalized patients included was too small to draw definitive conclusions regarding VE and durability of 3 doses in preventing hospitalization. Long-term follow-up is needed to evaluate the durability of both 100-µg and 50-µg booster doses in preventing infection and hospitalization. In conclusion, this study of mRNA-1273 found waning 2-dose VE against delta infection, high VE 3-dose VE against delta infection, and low 2-dose and 3-dose VE against omicron infection. Protection against omicron infection wanes within 3 months after dose 2, suggesting a need for a shorter interval between second and booster doses. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 8, 2022. ; (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 8, 2022. ; Table 1 . Characteristics of SARS-CoV-2 test positive cases and test negative controls, by variant O r g a n t r a n s p l a n t 3 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 8, 2022. M o d e l f o r o m i c r o n v a r i a n t a d j u s t e d f o r c o v a r i a t e s : B M I , C h a r l s o n c o m o r b i d i t y s c o r e , f r a i l t y i n d e x , k i d n e y d i s e a s e , d i a b e t e s , i m m u n o c o m p r o m i s e d s t a t u s , p r e g n a n c y s t a t u s a t i n d e x d a t e , h i s t o r y o f C O V I D -1 9 , n u m b e r o f o u t p a t i e n t a n d v i r t u a l v i s i t s , n u m b e r o f E D v i s i t s , n u m b e r o f h o s p i t a l i z a t i o n s , p r e v e n t i v e c a r e , m e d i c a l c e n t e r a r e a , s p e c i m e n t y p e . M o d e l s f o r i m m u n o c o m p r o m i s e d s t a t u s a n a l y s e s a r e u n c o n d i t i o n a l l o g i s t i c m o d e l s , a n d a r e a d j u s t e d f o r m a t c h i n g v a r i a b l e s a g e g r o u p s , s e x , a n d r a c e / e t h n i c i t y i n a d d i t i o n t o t h e c o v a r i a t e s a d j u s t e d i n c o n d i t i o n a l m o d e l s . c A d j u s t e d O R a n d a d j u s t e d V E a d j u s t e d a g e g r o u p w i t h 6 5 -7 4 y e a r o l d a n d 7 5 y e a r s a n d o l d e r g r o u p s c o m b i n e d , a n d d i d n o t a d j u s t f o r B M I , p r e g n a n c y s t a t u s a t i n d e x d a t e , h i s t o r y o f C O V I D -1 9 , n u m b e r o f o u t p a t i e n t a n d v i r t u a l v i s i t s , n u m b e r o f h o s p i t a l i z a t i o n s , s p e c i m e n t y p e , m e d i c a l c e n t e r a r e a d u e t o l a c k o f m o d e l c o n v e r g e n c e . d A d j u s t e d O R a n d a d j u s t e d V E d i d n o t a d j u s t f o r B M I , n u m b e r o f h o s p i t a l i z a t i o n s d u e t o l a c k o f m o d e l c o n v e r g e n c All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 8, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 8, 2022. ; Figure 1 . Vaccine effectiveness of 2-dose mRNA-1273 against omicron and delta variants by time since vaccination All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 8, 2022. ; https://doi.org/10.1101/2022.01.07.22268919 doi: medRxiv preprint Figure 2 . Vaccine effectiveness of 3-dose mRNA-1273 against omicron and delta variants by time since vaccination among immunocompetent population All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 8, 2022. ; https://doi.org/10.1101/2022.01.07.22268919 doi: medRxiv preprint improve care for our members and can be shared with the larger community. Julie Inc, provided critical input on specimen sequencing. Individual-level data reported in this study are not publicly shared. Upon request, and subject to review, KPSC may provide the deidentified aggregate-level data that support the findings of this study. Deidentified data (including participant data as applicable) may be shared upon approval of an analysis proposal and a signed data access agreement. This research was supported by Moderna Inc. All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare the following: HFT, BKA, YL, LSS, YT, JET, AF, JHK, GSL, SKC, HST, MA, and LQ are employees of Kaiser Permanente Southern California, which has been contracted by Moderna to conduct this study. KJB is an adjunct investigator at Kaiser Permanente Southern California. CAT is an employee of and a shareholder in Moderna Inc. HFT received funding from GlaxoSmithKline and Seqirus unrelated to this manuscript; HFT also served in advisory boards for Janssen and Pfizer. BKA received funding from GlaxoSmithKline, Dynavax, Seqirus, Pfizer and Genentech for work unrelated to this study and has served on advisory boards for GlaxoSmithKline. YL received funding from GlaxoSmithKline, All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 8, 2022. ; https://doi.org/10.1101/2022.01.07.22268919 doi: medRxiv preprint Seqirus and Pfizer unrelated to this manuscript. LSS received funding from GlaxoSmithKline, Dynavax, and Seqirus unrelated to this manuscript. YT received funding from GlaxoSmithKline unrelated to this manuscript. JET received funding from Pfizer unrelated to this manuscript. AF received funding from Pfizer, GlaxoSmithKline, and Gilead unrelated to this manuscript. JHK received funding from GlaxoSmithKline unrelated to this manuscript. GSL received funding from GlaxoSmithKline unrelated to this manuscript. SKC received funding from Pfizer and Pancreatic Cancer Action Network unrelated to this manuscript. HST received funding from GlaxoSmithKline, Pfizer, ALK, and Wellcome unrelated to this manuscript. MA received funding from Pfizer unrelated to this manuscript. LQ received funding from GlaxoSmithKline and Dynavax unrelated to this manuscript. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 8, 2022. ; Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa ) 95.1% (91.6%, 97.1%) 97.2% (94.1%, 98.7%) Sex Female 6%) Sex Female 191 (18.8%) 824 (81.2%) Medical writing and editorial assistance were provided by Srividya Ramachandran, PhD, Permanente for their partnership with us to improve their health. Their information, collected through our electronic health record systems, leads to findings that help us All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 8, 2022. Concept and design HFT, LSS, LQ, KJB,